+1 (888) 794-0077
« Return

Providing Support for Drug Discovery and Non-GLP Bioanalysis

Speed is essential for your in vitro and in vivo screening during drug discovery. Whether you are developing a small or large molecule drug, working with the right bioanalytical team is essential to your success. Look for a partner that provides comprehensive services that include method development, method qualification and sample collection protocol design. Your partner should deliver the right structure, procedures, and data quality that is needed for a successful drug candidate.

Experience a bioanalytical team that offers one of the most extensive technology platforms for small and large molecule bioanalysis. It is comprised of industry-leading instrumentation to support regional and global studies with rapid, precise and reproducible results. Using an existing library of validated methods and state-of-the-art instrumentation, our experienced discovery bioanalytical team has successfully expedited numerous projects to completion.

The bioanalytical team at WuXi AppTec offers optimized project workflows and robust state-of-the-art technology platforms that can rapidly develop and validate methods to support your drug discovery efforts for small and large molecule development. This includes biomarkers, immunogenicity and pharmacokinetic (PK) studies. Learn more about our non-GLP bioanalytical services by watching the video below.

Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.


As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

Related Posts

Five Ways LNP-mRNA is Shaping the Future of Medicine

Five Ways LNP-mRNA is Shaping the Future of Medicine

Lipid nanoparticle (LNP) mRNA technology has emerged as a transformative platform in modern medicine. While it first gained broad attention through vaccine applications, its success was built on decades of scientific discovery and bioanalytical innovation. Today, this powerful platform is expanding into applications across oncology, rare disorders, and other complex disease areas.

How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk

How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk

Safety pharmacology plays a critical role across all stages of drug discovery and development. In the context of translational medicine, it bridges nonclinical findings and clinical outcomes by characterizing a drug candidate’s on- and off-target effects. This insight supports the selection of compounds with favorable safety profiles for early clinical trials. Conducting safety pharmacology studies early in development is one of the most effective strategies for minimizing attrition risk and maintaining development timelines. These studies assess a compound’s impact on vital physiological systems—such as the central nervous, cardiovascular, and respiratory systems—enabling more informed and timely decision-making.